<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">Cardiovascular disease</z:e> (<z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e>, <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0004950'>peripheral vascular disease</z:hpo>) is the most important cause of mortality and morbidity among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Conventional risk factors contribute similarly to macrovascular complications in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and nondiabetic subjects, and therefore, other explanations have been sought for enhanced atherothrombosis in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Among characteristics specific for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> has recently been a focus of keen research </plain></SENT>
<SENT sid="3" pm="."><plain>A recent meta-analysis of 20 studies on nondiabetic subjects has demonstrated that in the nondiabetic range of glycemia (&lt;6.1 mmol/l), increased <z:chebi fb="105" ids="17234">glucose</z:chebi> is already associated with an increased risk for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Similarly, 12 recent prospective studies have convincingly indicated that <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> contributes to cardiovascular complications in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>The recently published U.K </plain></SENT>
<SENT sid="6" pm="."><plain>Prospective <z:mp ids='MP_0002055'>Diabetes</z:mp> Study has shown that intensive <z:chebi fb="105" ids="17234">glucose</z:chebi> control reduces effectively microvascular complications among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, but that its effect on the prevention of cardiovascular complications was limited </plain></SENT>
<SENT sid="7" pm="."><plain>Given the fact that in the U.K </plain></SENT>
<SENT sid="8" pm="."><plain>Prospective <z:mp ids='MP_0002055'>Diabetes</z:mp> Study, none of the treatment modalities was particularly effective in reducing <z:chebi fb="105" ids="17234">glucose</z:chebi>, this underestimates the true potential of the correction of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in the prevention of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>However, in addition to intensive therapy of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, other conventional risk factors should also be normalized to prevent <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>